Serum soluble TACI, a Blys receptor, is a powerful prognostic marker of outcome in chronic lymphocytic leukemia

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Kyrtsonis, Marie Christine ^a   Sarris, Katerina ^a   Koulieris, Efstathios ^a   Maltezas, Dimitrios ^a   Nikolaou, Eftychia ^a   Angelopoulou, Maria K ^a   Bartzis, Vassiliki ^a   Tzenou, Tatiana ^a   Dimou, Maria ^a   Siakandaris, Mariana P ^a   Viniou, Nora A ^a   Sachanas, Sotirios ^b   Kalpadakis, Christina ^b   Sfikakis, Petros P ^a   Pangalis, Gerassimos A ^b   Panayiotidis, Panayiotis ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b ATHENS MEDICAL CENTER   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; BETA 2 MICROGLOBULIN; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; BLYS RECEPTOR; TNFRSF13B PROTEIN, HUMAN; TUMOR MARKER; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ANEMIA; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CORRELATIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; INVESTIGATIVE PROCEDURES; LIGHT CHAIN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; THROMBOCYTOPENIA; BLOOD; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84926465309     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/159632     Document Type: Article

References (21)

1. S. H. Swerdlow, E. Campo, and N. E. Harris, Eds. , WHOClassification of Tumours of Haematipoetic and Lymphoid Tissues, Lyon IARC Press, 2008.
2. M. Hallek, B. D. Cheson, D. Catovsky et al., "Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines, " Blood, vol. 111, no. 12, pp. 5446-5456, 2008.
3. E. Matutes, K. Owusu-Ankomah, R. Morilla et al., "The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL, " Leukemia, vol. 8, no. 10, pp. 1640-1645, 1994.
4. P. Cramer and M. Hallek, "Prognostic factors in chronic lymphocytic leukemia-what dowe need to knowØ Nature Reviews Clinical Oncology, vol. 8, no. 1, pp. 38-47, 2011.
5. A. J. Novak, R. J. Bram, N. E. Kay, and D. F. Jelinek, "Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival, " Blood, vol. 100, no. 8, pp. 2973-2979, 2002.
6. M.-C. Kyrtsonis, K. Sarris, T. Tzenou, and D. Maltezas, "Blymphocyte stimylator (BLyS) role in chronic lymphocytic leukaemia (CLL), Waldenströms Macroglobulinaemia (WM) and Multiple Myeloma (MM). Treatment strategies, " Hematology, 2013.
7. A. Craxton, D. Magaletti, E. J. Ryan, and E. A. Clark, "Macrophage-and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF, " Blood, vol. 101, no. 11, pp. 4464-4471, 2003.
8. F. Melchers, "Actions of BAFF in B cellmaturation and its effects on the development of autoimmune disease, " Annals of the Rheumatic Diseases, vol. 62, supplement 2, pp. ii25-ii27, 2003.
9. F. Mackay and C. Ambrose, "The TNF family members BAFF and APRIL: the growing complexity, " Cytokine and Growth Factor Reviews, vol. 14, no. 3-4, pp. 311-324, 2003.
10. F. Mackay and J. L. Browning, "BAFF: a fundamental survival factor for B cells, " Nature Reviews Immunology, vol. 2, no. 7, pp. 465-475, 2002.
11. F. Mackay, P. Schneider, P. Rennert, and J. Browning, "BAFF and APRIL: a tutorial on B cell survival, Annual Reviewof Immunology, vol. 21, pp. 231-264, 2003.
12. G. Ferrer, K. Hodgson, E. Montserrat, and C. Moreno, "B cell activator factor and a proliferation-inducing ligand at the crossroad of chronic lymphocytic leukemia and autoimmunity," Leukemia and Lymphoma, vol. 50, no. 7, pp. 1075-1082, 2009.
13. L. Planelles, S. Castillo-Gutiérrez, J. P. Medema, A. Morales-Luque, H. Merle-Béral, and M. Hahne, "APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance ofAPRIL for survival, " Haematologica, vol. 92, no. 9, pp. 1284-1285, 2007.
14. S. Molica, G. Digiesi, C. Battaglia et al., "Baff serum level predicts time to first treatment in early chronic lymphocytic leukaemia," European Journal of Haematology, vol. 85, no. 4, pp. 314-320, 2010.
15. S. M. Ansell, A. J. Novak, S. Ziesmer et al., "Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma, " The American Journal of Hematology, vol. 84, no. 2, pp. 71-73, 2009.
16. J.-F. Rossi, J. Moreaux, D. Hose et al., "Atacicept in relapsed/refractory multiple myeloma or active Waldenströms macroglobulinemia: a phase I study, " British Journal of Cancer, vol. 101, no. 7, pp. 1051-1058, 2009.
17. N. S. Raje, R. J. Hohl, E. A. Faber et al., "Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma, " Journal of Clinical Oncology, vol. 29, supplement, abstract 8012, 2011.
18. M. C. Kyrtsonis, K. Sarris, G. Pangalis et al., "Contradictory impact of serumBLyS levels in Chronic Lymphocytic leukemia, Waldestroms macroglobulinemia and Multiple Myeloma," EHA, Abstr 741, 2012.
19. G. Pratt, S. Harding, R. Holder et al., "Abnormal serumfree light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia," The British Journal of Haematology, vol. 144, no. 2, pp. 217-222, 2009.
20. F. Morabito, R. de Filippi, L. Laurenti et al., "The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia, " Blood, vol. 118, no. 24, pp. 6353-6361, 2011.
21. K. Sarris, D. Maltezas, E. Koulieris et al., "Prognostic significance of serum free light chains in chronic lymphocytic leukemia," Advances in Hematology, vol. 2013, Article ID 359071, 7 pages, 2013.